At a glance: Black cohosh is the rhizome and root of Actaea racemosa L. (older medicinal literature commonly uses the synonym Cimicifuga racemosa). It is principally used for menopausal symptoms. Some modern meta-analyses report improvements in overall menopausal symptoms and hot flushes with particular extracts, while other reviews and guidelines have found the evidence inconsistent. Rare reports of serious liver injury have occurred in users of products labelled as black cohosh, although causality is often uncertain and product adulteration is a recognised quality problem.[1][2][3]
Botanical profile
- Accepted modern name: Actaea racemosa L.
- Common medicinal synonym: Cimicifuga racemosa (L.) Nutt.
- Common name: black cohosh.
- Family: Ranunculaceae.
- Medicinal part: rhizome and root.
- EMA herbal drug name: Cimicifugae rhizoma.[1]
Black cohosh is native to North America. It should not be confused with blue cohosh (Caulophyllum thalictroides), an unrelated plant with a different chemistry and markedly different safety concerns.[2]
Major constituent groups
Black cohosh preparations contain several classes of compounds, including:
- cycloartane triterpene glycosides, often used as analytical markers;
- phenolic and hydroxycinnamic-acid derivatives;
- cimicifugic and fukinolic acid-related compounds; and
- smaller quantities of other phenolics and nitrogen-containing constituents.
The pharmacology is not reducible to a single established “active ingredient”, and different extraction solvents can produce materially different preparations.
Traditional use
Black cohosh has a long North American medicinal history. Indigenous uses included menstrual and reproductive complaints, pain associated with childbirth, rheumatic and muscular pain, and some respiratory complaints. It was later adopted by Eclectic physicians, who used it particularly for painful or irregular menstruation, menopausal symptoms, uterine cramping, neuralgic pain and rheumatic or muscular tension.
Contemporary herbal practice
Western herbalists commonly use black cohosh in menopausal and menstrual formulations, especially where vasomotor symptoms coexist with muscular tension, aching or a sense of nervous-system irritability. It may be prescribed alone as a characterised extract or combined with other herbs according to the individual pattern. Traditional practitioner texts preserve a broader musculoskeletal and gynaecological picture than the modern menopause-only marketing of the herb.
EMA regulatory assessment
The EMA HMPC monograph covers defined black-cohosh dry extracts prepared using specified solvents. Revision 1 was published in 2018, and the EMA published an assessment-report addendum in February 2026 while the next periodic review was in progress.[1]
This preparation specificity matters when comparing trial results. “Black cohosh” is less precise than naming the extract.
Menopausal symptoms: what does the evidence say?
The evidence has evolved and remains somewhat inconsistent. NCCIH summarises a 2023 review of 22 studies in which black-cohosh-containing preparations were associated with improvements in overall menopausal symptoms and hot flushes but not anxiety or depressive symptoms.[2]
The 2023 pairwise meta-analysis reported significant improvements in overall menopausal symptoms and hot flushes compared with placebo across the included trials.[3]
Older systematic reviews were less confident. A 2008 review of six double-blind randomised trials concluded that the evidence did not consistently demonstrate an effect, while a 2010 meta-analysis found an overall reduction in vasomotor symptoms but substantial heterogeneity.[4][5]
Why can reviews disagree?
Possible reasons include:
- different extracts and extraction methods;
- different diagnostic definitions and symptom scales;
- monopreparations versus combination products;
- variation in study duration and menopause stage;
- small trial sizes; and
- industry involvement in parts of the evidence base.
Students should therefore report the extract and funding/conflict-of-interest context when it is relevant rather than simply choosing the most favourable meta-analysis.
Is black cohosh an oestrogen?
Black cohosh is often casually described online as a “phytoestrogen”, but its mechanism is not settled and it should not be treated as botanical oestrogen replacement. Research has explored serotonergic, dopaminergic and other pathways as well as hormonal hypotheses.
Clinical claims should rest on trial outcomes rather than assuming that a proposed receptor mechanism explains the whole effect.
Safety and liver injury
Most people in clinical studies tolerate black cohosh reasonably well, with mild adverse effects such as gastrointestinal upset, headache, rash or spotting reported in some users.[2]
Rare cases of liver damage, some serious, have been reported in people taking products labelled as black cohosh. Causality is uncertain in many reports, and commercial-product misidentification or adulteration has been documented. Nevertheless, symptoms such as dark urine, jaundice, marked fatigue or unexplained abdominal symptoms after starting a product warrant medical assessment.[2]
Product identity matters
NCCIH notes that some commercial products sold as black cohosh have contained the wrong herb or undeclared mixtures.[2] This matters both for clinical safety and for interpreting adverse-event reports: an adverse event linked to a mislabelled product is not automatically evidence about authentic Actaea racemosa, but it remains evidence about the real-world risk of the marketplace.
Hormone-sensitive conditions
Safety in people with a history of hormone-sensitive conditions such as breast or uterine cancer remains uncertain. A person in this situation should not infer safety from the fact that black cohosh is not simply an oestrogen.
Pregnancy and breastfeeding
Black cohosh is not considered an appropriate self-treatment during pregnancy or breastfeeding. NCCIH notes that safety is uncertain and that use in pregnancy may not be safe.[2]
Student note: common evidence traps
- Actaea racemosa and Cimicifuga racemosa refer to the same medicinal species in modern/older nomenclature; blue cohosh is a different plant.
- Record the extract, not merely “black cohosh”.
- Do not hide disagreement between systematic reviews.
- Do not call black cohosh “natural HRT”.
- Distinguish an adverse-event signal from proof of causality, but do not dismiss the signal.
- Check whether a menopause trial used black cohosh alone or a combination product.
References
- European Medicines Agency, Committee on Herbal Medicinal Products. Cimicifugae rhizoma — Cimicifuga racemosa (L.) Nutt., rhizome. EU herbal monograph and assessment documents. EMA. Revision 1 published 2018; assessment-report addendum published February 2026.
- National Center for Complementary and Integrative Health. Black Cohosh: Usefulness and Safety. NCCIH. Updated November 2024; consulted September 2026.
- Sadahiro R, et al. Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis. Menopause. 2023;30(7):766–773. doi:10.1097/GME.0000000000002196. PubMed.
- Leach MJ, Moore V. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: systematic review of efficacy literature represented in PubMed record. PubMed.
- Shams T, Setia MS, Hemmings R, et al. Efficacy of black-cohosh-containing preparations on menopausal symptoms: a meta-analysis. Alternative Therapies in Health and Medicine. 2010;16(1):36–44. PubMed.
Additional materia medica sources
- ESCOP. Cimicifugae rhizoma — Black cohosh, ESCOP Monographs.
- Blumenthal M, et al., eds. The Complete German Commission E Monographs. American Botanical Council; 1998.
- Mills S, Bone K. Principles and Practice of Phytotherapy. 2nd ed. Elsevier; 2013.
- Hoffmann D. Medical Herbalism. Healing Arts Press; 2003.
Last reviewed: 20 September 2026. Educational reference only; not an individual prescribing guide.
← Return to the Herbal Monograph Library | Herbal Medicine Safety and Interactions